Compare 3-D Matrix Ltd. with Similar Stocks
Dashboard
1
With a growth in Net Sales of 16.85%, the company declared Outstanding results in Apr 25
- The company has declared positive results for the last 5 consecutive quarters
- NET SALES(HY) At JPY 3,659.7 MM has Grown at 32.96%
- INVENTORY TURNOVER RATIO(HY) Highest at 0.94%
- DEBT-EQUITY RATIO (HY) Lowest at 61.39 %
2
With ROE of -37.31%, it has a risky valuation with a 5.96 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
JPY 57,702 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.04
0.76%
14.59
Revenue and Profits:
Net Sales:
1,875 Million
(Quarterly Results - Apr 2025)
Net Profit:
-1,107 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
41.03%
0%
41.03%
6 Months
94.96%
0%
94.96%
1 Year
251.52%
0%
251.52%
2 Years
321.82%
0%
321.82%
3 Years
48.24%
0%
48.24%
4 Years
7.66%
0%
7.66%
5 Years
49.68%
0%
49.68%
3-D Matrix Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
59.69%
EBIT Growth (5y)
9.33%
EBIT to Interest (avg)
-242.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
1.06
Tax Ratio
0.89%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.96
EV to EBIT
-15.36
EV to EBITDA
-15.36
EV to Capital Employed
4.40
EV to Sales
2.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-28.64%
ROE (Latest)
-37.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Oct 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY
Apr'25
Apr'24
Change(%)
Net Sales
1,874.70
1,604.40
16.85%
Operating Profit (PBDIT) excl Other Income
-550.20
-498.70
-10.33%
Interest
14.80
21.00
-29.52%
Exceptional Items
6.50
44.80
-85.49%
Consolidate Net Profit
-1,107.40
444.40
-349.19%
Operating Profit Margin (Excl OI)
-293.50%
-310.90%
1.74%
USD in Million.
Net Sales
YoY Growth in quarter ended Apr 2025 is 16.85% vs 112.33% in Apr 2024
Consolidated Net Profit
YoY Growth in quarter ended Apr 2025 is -349.19% vs 222.32% in Apr 2024
Annual Results Snapshot (Consolidated) - Apr'25
Apr'25
Apr'24
Change(%)
Net Sales
6,934.10
4,588.80
51.11%
Operating Profit (PBDIT) excl Other Income
-1,156.20
-2,117.00
45.38%
Interest
74.40
83.80
-11.22%
Exceptional Items
4.60
-164.80
102.79%
Consolidate Net Profit
-2,501.20
-255.50
-878.94%
Operating Profit Margin (Excl OI)
-166.70%
-461.30%
29.46%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2025 is 51.11% vs 98.30% in Apr 2024
Consolidated Net Profit
YoY Growth in year ended Apr 2025 is -878.94% vs 89.55% in Apr 2024
About 3-D Matrix Ltd. 
3-D Matrix Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






